Therapeutic strategies in glioblastoma have focused on blocking MGMT activation, either through epigenetic agents that modulate the methylated state of the MGMT gene promoter or through direct inhibition of the MGMT protein (Figure 2). The gene discussed is MGMT; the disease is glioblastoma.